1. Epstein AM. The outcomes movement—will it get us where we want to go?N Engl J Med1990;323:266–70.
2.
2. Scheinberg L, Smith CR. Rehabilitation of patients with multiple sclerosis. Neur Clin1987;5:585–600.
3.
3. Erickson RP, Lie MR, Wineinger MA. Rehabilitation in multiple sclerosis. Mayo Clin Proc1989;64:818–28.
4.
4. Maloney FP, Burks JS, Ringel SP. Interdisciplinary rehabilitation of multiple sclerosis and neuromuscular disorders. Philadelphia: J.B. Lippincott Company, 1985.
5.
5. Schapiro RT. Symptom management in multiple sclerosis. New York, Demos Publications, 1987.
6.
6. Scheinberg LC, Holland NJ. Multiple sclerosis: a guide for patients and their families. New York, Raven Press, 1987.
7.
7. Feigenson JS, Scheinberg L, et al. The cost-effectiveness of multiple sclerosis rehabilitation: a model. Neur1981;31:1316–22.
8.
8. Greenspun B, Stineman M, Agri R. Multiple sclerosis and rehabilitation outcome. Arch Phys Med Rehabil1987;68:434–37.
9.
9. Carey RG, Seibert JH, Posavac EJ. Who makes the most progress in inpatient rehabilitation? An analysis of functional gain. Arch Phys Med Rehabil1988;69:337–43.
10.
10. Kraft GH, Freal JE, Coryell JK. Disability, disease duration, and rehabilitation service needs in multiple sclerosis: patient perspectives. Arch Phys Med Rehabil1986;67:164–68.
11.
11. Halstead LS. Team care in chronic illness: a critical review of the literature of the past 25 years. Arch Phys Med Rehabil1976;57:507–11.
12.
12. Keith AR. The comprehensive treatment team in rehabilitation. Arch Phys Med Rehabil1991;72:269–74.
13.
13. Banja JD. Rehabilitation and empowerment. Arch Phys Med Rehabil1990;71:614–15.
14.
14. World Health Organization: International Classification of Impairments, Disabilities and Handicaps: A Manual of Classification Relating to Consequences of Disease. Geneva, World Health Organization.
15.
15. Slater RJ. Criteria and uses of the Minimum Record of Disability in multiple sclerosis. ACTA Neurol Scand1984;70 (suppl101):16–20.
16.
16. Hauser SI, Dawson DM, et al. Intensive immunosuppression in progressive multiple sclerosis. New Engl J Med1983;308(4):173–80.